Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-446.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -61.46% |
| Return on Assets (Trailing 12 Months) | -50.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.15 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.76 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.47 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.54 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 165.03M |
| Free Float | 141.69M |
| Market Capitalization | $3.11B |
| Average Volume (Last 20 Days) | 2.71M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.14% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |